Amendments to the Claims:

Please amend the claims as follows:

Claim 1 (Currently amended): A pharmaceutical aerosol formulation comprising:

(i) a therapeutic effective amount of particulate medicament selected from a compound of formula (I)



(I)

or a salt, solvate or physiologically functional derivative thereof, wherein

R_a represents C_{1-6} alkyl or C_{1-6} haloalkyl;

R_b represents -C(=O)-aryl or -C(=O)-heteroaryl;

R_c represents hydrogen[[,]] or methyl ~~(which may be in either the α or β configuration) or methylene~~;

R_d and R_e are the same or different and each represents hydrogen or halogen; and

⎓ represents a single or a double bond

and / or a compound of formula (II)



(II)

or a salt, solvate or physiologically functional derivative thereof, wherein:

m is an integer of from 2 to 8;

n is an integer of from 3 to 11;

with the proviso that m + n is 5 to 19;

R^1 is $-XSO_2NR^6R^7$

wherein X is $-(CH_2)_p-$ or C_{2-6} alkenylene;

R^6 and R^7 are independently selected from hydrogen, C_{1-6}alkyl, C_{3-7}cycloalkyl, $C(O)NR^8R^9$, phenyl, and phenyl (C_{1-4}alkyl)-, or R^6 and R^7, together with the nitrogen to which they are bonded, form a 5-, 6-, or 7-membered nitrogen containing ring,

and R^6 and R^7 are each optionally substituted by one or two groups selected from halo, C_{1-6}alkyl, C_{1-6}haloalkyl, C_{1-6}alkoxy, hydroxy-substituted C_{1-6}alkoxy, $-CO_2R^8$, $-SO_2NR^8R^9$, $-CONR^8R^9$, $-NR^8C(O)R^9$, or a 5-, 6- or 7-membered heterocylic ring;

R^8 and R^9 are independently selected from hydrogen, C_{1-6}alkyl, C_{3-6}cycloalkyl, phenyl, and phenyl (C_{1-4}alkyl)-; and

p is an integer of from 0 to 6;

R^2 and R^3 are independently selected from hydrogen, C_{1-6}alkyl, C_{1-6}alkoxy, halo, phenyl, and C_{1-6}haloalkyl; and

R^4 and R^5 are independently selected from hydrogen and C_{1-4}alkyl with the proviso that the total number of carbon atoms in R^4 and R^5 is not more than 4;

(ii) a propellant selected from the group consisting of ~~comprising~~ 1,1,1,2-tetrafluoroethane, ~~or~~ 1,1,1,2,3,3,3-heptofluoro-n-propane, ~~1,1,1,2,3,3,3 heterofluoro-n propane~~ and mixtures thereof; and

(iii) the surfactant [(7,7,8,8,8-pentafluorooctyl)oxy]acetic acid.

Claims 2-5 (Canceled)

Claim 6 (Currently amended): A pharmaceutical aerosol formulation according to ~~any one of claims~~ claim 1 [[to 5]] in which the surfactant is present in the range 0.5% to 10%w/w relative to the medicament.

Claim 7 (Currently amended): A pharmaceutical aerosol formulation according to ~~any one of claims~~ claim 1 [[to 6]] in which the propellant is 1,1,1,2-tetrafluoroethane.

Claim 8 (Currently amended): A process for the preparation of a pharmaceutical aerosol formulation according to ~~any one of claims~~ claim 1 [[to 7]] which comprises dispersal of a compound of formula (I) and/or (II) as described in claim 1 and the chosen surfactant compound in the selected propellant in an appropriate container.

Claims 9 and 10 (Canceled)

Claim 11 (Currently amended): A method of treatment or prophylaxis of respiratory disorders which comprises administering to a patient in need thereof a pharmaceutical aerosol formulation according to ~~any one of claims~~ claim 1 [[to 7]].

Claim 12 (Currently amended): A metered dose inhaler containing therein a pharmaceutical aerosol formulation according to ~~any one of claims~~ claim 1 [[to 7]].

Claims 13 and 14 (Canceled)

Claim 15 (New): A pharmaceutical aerosol formulation consisting essentially of:

(i) a therapeutic effective amount of particulate medicament selected from a compound of formula (I)



(I)

or a salt, solvate or physiologically functional derivative thereof, wherein

R_a represents C_{1-6} alkyl or C_{1-6} haloalkyl;

R_b represents -C(=O)-aryl or -C(=O)-heteroaryl;

R_c represents hydrogen or methyl;

R_d and R_e are the same or different and each represents hydrogen or halogen; and

⎓ represents a single or a double bond

and / or a compound of formula (II)



(II)

or a salt, solvate or physiologically functional derivative thereof, wherein:

m is an integer of from 2 to 8;

n is an integer of from 3 to 11;

with the proviso that m + n is 5 to 19;

R^1 is $-XSO_2NR^6R^7$

wherein X is $-(CH_2)_p-$ or C_{2-6} alkenylene;

R^6 and R^7 are independently selected from hydrogen, C_{1-6}alkyl, C_{3-7}cycloalkyl, $C(O)NR^8R^9$, phenyl, and phenyl (C_{1-4}alkyl)-,

or R^6 and R^7, together with the nitrogen to which they are bonded, form a 5-, 6-, or 7-membered nitrogen containing ring,

and R^6 and R^7 are each optionally substituted by one or two groups selected from halo, C_{1-6}alkyl, C_{1-6}haloalkyl, C_{1-6}alkoxy, hydroxy-substituted C_{1-6}alkoxy, $-CO_2R^8$, $-SO_2NR^8R^9$, $-CONR^8R^9$, $-NR^8C(O)R^9$, or a 5-, 6- or 7-membered heterocylic ring;

R^8 and R^9 are independently selected from hydrogen, C_{1-6}alkyl, C_{3-6}cycloalkyl, phenyl, and phenyl (C_{1-4}alkyl)-; and

p is an integer of from 0 to 6;

R^2 and R^3 are independently selected from hydrogen, C_{1-6}alkyl, C_{1-6}alkoxy, halo, phenyl, and C_{1-6}haloalkyl; and

R^4 and R^5 are independently selected from hydrogen and C_{1-4}alkyl with the proviso that the total number of carbon atoms in R^4 and R^5 is not more than 4;

(ii) a propellant selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptofluoro-n-propane, and mixtures thereof; and

(iii) the surfactant [(7,7,8,8,8-pentafluorooctyl)oxy]acetic acid.

Claim 16 (New): A pharmaceutical aerosol formulation according to claim 15 in which the surfactant is present in the range 0.5% to 10%w/w relative to the medicament.

Claim 17 (New): A pharmaceutical aerosol formulation comprising:
(i) a therapeutic effective amount of particulate medicament, wherein the particulate medicament is 3-(4-{[6-({(2*R*)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl) phenyl]ethyl} amino)hexyl]oxy}butyl) benzenesulfonamide;
(ii) a propellant selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptofluoro-n-propane, and mixtures thereof; and
(iii) the surfactant [(7,7,8,8,8-pentafluorooctyl)oxy]acetic acid.

Claim 18 (New): A pharmaceutical aerosol formulation according to claim 17 in which the surfactant is present in the range 0.5% to 10%w/w relative to the medicament.

Claim 19 (New): A method of treatment or prophylaxis of respiratory disorders which comprises administering to a patient in need thereof a pharmaceutical aerosol formulation according to claim 17.

Claim 20 (New): A metered dose inhaler containing therein a pharmaceutical aerosol formulation according to claim 17.

Claim 21 (New): A pharmaceutical aerosol formulation comprising:

(i) a therapeutic effective amount of particulate medicament, wherein the particulate medicament is 6α, 9α-difluoro-17α-[(2-furanylcarbonyl)oxy]-11β-hydroxy-16α-methyl-3-oxo-androsta-1,4-diene-17β-carbothioic acid *S*-fluoromethyl ester;

(ii) a propellant selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptofluoro-n-propane, and mixtures thereof; and

(iii) the surfactant [(7,7,8,8,8-pentafluorooctyl)oxy]acetic acid.

Claim 22 (New): A pharmaceutical aerosol formulation according to claim 21 in which the surfactant is present in the range 0.5% to 10%w/w relative to the medicament.

Claim 23 (New): A method of treatment or prophylaxis of respiratory disorders which comprises administering to a patient in need thereof a pharmaceutical aerosol formulation according to claim 21.

Claim 24 (New): A metered dose inhaler containing therein a pharmaceutical aerosol formulation according to claim 21.

Claim 25 (New): A pharmaceutical aerosol formulation comprising:

(i) a therapeutic effective amount of particulate medicament, wherein the particulate medicament is 3-(4-{[6-({(2*R*)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl) phenyl]ethyl} amino)hexyl]oxy}butyl) benzenesulfonamide in combination with 6α, 9α-difluoro-17α-[(2-furanylcarbonyl)oxy]-11β-hydroxy-16α-methyl-3-oxo-androsta-1,4-diene-17β-carbothioic acid *S*-fluoromethyl ester;

(ii) a propellant selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptofluoro-n-propane, and mixtures thereof; and

(iii) the surfactant [(7,7,8,8,8-pentafluorooctyl)oxy]acetic acid.

Claim 26 (New): A pharmaceutical aerosol formulation according to claim 25 in which the surfactant is present in the range 0.5% to 10%w/w relative to the medicament.

Claim 27 (New): A method of treatment or prophylaxis of respiratory disorders which comprises administering to a patient in need thereof a pharmaceutical aerosol formulation according to claim 25.

Claim 28 (New): A metered dose inhaler containing therein a pharmaceutical aerosol formulation according to claim 25.

Claim 29 (New): A pharmaceutical aerosol formulation consisting essentially of:
(i) a therapeutic effective amount of particulate medicament, wherein the particulate medicament is 3-(4-{[6-({(2*R*)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl) phenyl]ethyl} amino)hexyl]oxy}butyl) benzenesulfonamide;
(ii) a propellant selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptofluoro-n-propane, and mixtures thereof; and
(iii) the surfactant [(7,7,8,8,8-pentafluorooctyl)oxy]acetic acid.

Claim 30 (New): A pharmaceutical aerosol formulation according to claim 29 in which the surfactant is present in the range 0.5% to 10%w/w relative to the medicament.

Claim 31 (New): A method of treatment or prophylaxis of respiratory disorders which comprises administering to a patient in need thereof a pharmaceutical aerosol formulation according to claim 29.

Claim 32 (New): A metered dose inhaler containing therein a pharmaceutical aerosol formulation according to claim 29.

Claim 33 (New): A pharmaceutical aerosol formulation consisting essentially of:

(i) a therapeutic effective amount of particulate medicament, wherein the particulate medicament is 6α, 9α-difluoro-17α-[(2-furanylcarbonyl)oxy]-11β-hydroxy-16α-methyl-3-oxo-androsta-1,4-diene-17β-carbothioic acid *S*-fluoromethyl ester;

(ii) a propellant selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptofluoro-n-propane, and mixtures thereof; and

(iii) the surfactant [(7,7,8,8,8-pentafluorooctyl)oxy]acetic acid.

Claim 34 (New): A pharmaceutical aerosol formulation according to claim 33 in which the surfactant is present in the range 0.5% to 10%w/w relative to the medicament.

Claim 35 (New): A method of treatment or prophylaxis of respiratory disorders which comprises administering to a patient in need thereof a pharmaceutical aerosol formulation according to claim 33.

Claim 36 (New): A metered dose inhaler containing therein a pharmaceutical aerosol formulation according to claim 33.

Claim 37 (New): A pharmaceutical aerosol formulation consisting essentially of:

(i) a therapeutic effective amount of particulate medicament, wherein the particulate medicament is 3-(4-{[6-({(2*R*)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl) phenyl]ethyl} amino)hexyl]oxy}butyl) benzenesulfonamide in combination with 6α, 9α-difluoro-17α-[(2-furanylcarbonyl)oxy]-11β-hydroxy-16α-methyl-3-oxo-androsta-1,4-diene-17β-carbothioic acid *S*-fluoromethyl ester;

(ii) a propellant selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptofluoro-n-propane, and mixtures thereof; and

(iii) the surfactant [(7,7,8,8,8-pentafluorooctyl)oxy]acetic acid.

Claim 38 (New): A pharmaceutical aerosol formulation according to claim 37 in which the surfactant is present in the range 0.5% to 10%w/w relative to the medicament.

Claim 39 (New): A method of treatment or prophylaxis of respiratory disorders which comprises administering to a patient in need thereof a pharmaceutical aerosol formulation according to claim 37.

Claim 40 (New): A metered dose inhaler containing therein a pharmaceutical aerosol formulation according to claim 37.